Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (3): 533-541.DOI: 10.19852/j.cnki.jtcm.2023.03.003
Previous Articles Next Articles
Efficacy of Buzhong Yiqi decoction (补中益气汤) on benign prostatic hyperplasia and its possible mechanism
JIA Lihua1(
), KUANG Haodan2, XU Yuan3()
- 1 Department of urology, Jinhua Hospital of TCM, Jinhua 321000, China
2 Zhejiang Chinese Medical University college of pharmacy, Hangzhou 310053, China
3 Ningbo medical center Lihuili Hospital, Ningbo 315100, China
-
Received:2021-10-12Accepted:2022-01-27Online:2023-06-15Published:2023-04-28 -
Contact:XU Yuan, Ningbo medical center Lihuili Hospital, Ningbo 315100, China. xu565831937@163.com. Telephone: +86-574-87018617
JIA Lihua, Department of urology, Jinhua Hospital of TCM, Jinhua 321000, China. jlhua666@163.com
Cite this article
JIA Lihua, KUANG Haodan, XU Yuan. Efficacy of Buzhong Yiqi decoction (补中益气汤) on benign prostatic hyperplasia and its possible mechanism[J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 533-541.
share this article
Table 1 PCR primers
| Gene | Sequence |
|---|---|
| IL-6 | F: 5′-TGGCTGCAGGACATGACAACT-3′ R: 5′-ATCTGAGGTGCCCATGCTACA-3′ |
| IL-1β | F: 5′-CTGATGGCCCTAAACAGATGAAG-3′ R: 5′-GGTCGGAGATTCGTAGCAGCTGGAT-3′ |
| TNF-α | F: 5′-AAACACACGAGACGCTGAAG-3′ R: 5′-ATCCAGTGAGTTCCGAAAGC-3′ |
| β-actin | F: 5'-TCTTGGGTATGGAATCCTGTGGCA-3' R: 5'-ACAGCACTGTGTTGGCATAGAGGT-3' |
Table 1 PCR primers
| Gene | Sequence |
|---|---|
| IL-6 | F: 5′-TGGCTGCAGGACATGACAACT-3′ R: 5′-ATCTGAGGTGCCCATGCTACA-3′ |
| IL-1β | F: 5′-CTGATGGCCCTAAACAGATGAAG-3′ R: 5′-GGTCGGAGATTCGTAGCAGCTGGAT-3′ |
| TNF-α | F: 5′-AAACACACGAGACGCTGAAG-3′ R: 5′-ATCCAGTGAGTTCCGAAAGC-3′ |
| β-actin | F: 5'-TCTTGGGTATGGAATCCTGTGGCA-3' R: 5'-ACAGCACTGTGTTGGCATAGAGGT-3' |
Figure 1 BZYQD “Herb-Compound-Target-Disease” network Round yellow nodes stand for putative targets of ingredients contained in BZYQD; Green diamonds stand for herbs; Blue triangle stand for therapeutic targets for BPH; Round red node stands for the disease of BPH. BZYQD: Buzhong yiqi decoction; BPH: benign prostatic hyperplasia.
Figure 1 BZYQD “Herb-Compound-Target-Disease” network Round yellow nodes stand for putative targets of ingredients contained in BZYQD; Green diamonds stand for herbs; Blue triangle stand for therapeutic targets for BPH; Round red node stands for the disease of BPH. BZYQD: Buzhong yiqi decoction; BPH: benign prostatic hyperplasia.
Figure 2 Target protein interaction network Round nodes stand for therapeutic targets for BPH and the number of edges from Target protein network. BPH: benign prostatic hyperplasia.
Figure 2 Target protein interaction network Round nodes stand for therapeutic targets for BPH and the number of edges from Target protein network. BPH: benign prostatic hyperplasia.
Figure 3 Gene function and KEGG pathway enrichment. A: biological process (BP); B: cell component (CC); C: molecular function (MF); D: KEGG pathway enrichment. The X-axis is the magnitude of P value, and the Y-axis is the path name. The size of the bubble chart represented the count number, and the darker the color, the smaller P value.
Figure 3 Gene function and KEGG pathway enrichment. A: biological process (BP); B: cell component (CC); C: molecular function (MF); D: KEGG pathway enrichment. The X-axis is the magnitude of P value, and the Y-axis is the path name. The size of the bubble chart represented the count number, and the darker the color, the smaller P value.
Figure 4 Molecular docking results of Quercetin and MAPK8 and IL-6 A: the molecular docking result of Quercetin and MAPK8 (P38) (3D). B: the molecular docking result of Quercetin and IL-6 (3D). C: the molecular docking result of Quercetin and MAPK8 (P38) (2D). D: The molecular docking result of Quercetin and IL-6 (2D).
Figure 4 Molecular docking results of Quercetin and MAPK8 and IL-6 A: the molecular docking result of Quercetin and MAPK8 (P38) (3D). B: the molecular docking result of Quercetin and IL-6 (3D). C: the molecular docking result of Quercetin and MAPK8 (P38) (2D). D: The molecular docking result of Quercetin and IL-6 (2D).
Figure 5 Anti-proliferative effect of quercetin on BPH-1 cells by MTT assay and quercetin inhibited the production of IL-1β, TNF-α, IL-6 A: quercetin was at the dose of 15, 30, 60, 120 μM and incubation time was at 12, 24, 48, 72 h; B-D: productions of interleukin -6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β) in culture supernatants were detected by enzyme-linked immunosorbent assay kit. E-G: expressions of IL-1β, TNF-α, IL-6 mRNA were measured by RT-RCR. Control group: quercetin 0 μM, 24 h; Que-15: quercetin 15 μM, 24 h; Que-60: quercetin 60 μM, 24 h; Data are expressed as mean?±?standard deviation of three independent experiments. aP?<?0.01 compared with Normal group; bP?<?0.01 compared with Model group.
Figure 5 Anti-proliferative effect of quercetin on BPH-1 cells by MTT assay and quercetin inhibited the production of IL-1β, TNF-α, IL-6 A: quercetin was at the dose of 15, 30, 60, 120 μM and incubation time was at 12, 24, 48, 72 h; B-D: productions of interleukin -6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β) in culture supernatants were detected by enzyme-linked immunosorbent assay kit. E-G: expressions of IL-1β, TNF-α, IL-6 mRNA were measured by RT-RCR. Control group: quercetin 0 μM, 24 h; Que-15: quercetin 15 μM, 24 h; Que-60: quercetin 60 μM, 24 h; Data are expressed as mean?±?standard deviation of three independent experiments. aP?<?0.01 compared with Normal group; bP?<?0.01 compared with Model group.
Figure 6 Quercetin inhibited the expression of p-P38 in the BPH-1 cells. A: Western bot was used to detect the expression of p-P38, P38, MMP-9 and β-actin. B-C: The statistical graph of MMP-9 and P38/p-P38 protein expression which were fold over control group. Control group: quercetin 0 μM, 24 h; Que-15: quercetin 15 μM, 24 h; Que-60: quercetin 60 μM, 24 h; Data are expressed as mean?±?standard deviation of three independent experiments. aP?<?0.01 compared with Normal group; bP?<?0.01 compared with Model group.
Figure 6 Quercetin inhibited the expression of p-P38 in the BPH-1 cells. A: Western bot was used to detect the expression of p-P38, P38, MMP-9 and β-actin. B-C: The statistical graph of MMP-9 and P38/p-P38 protein expression which were fold over control group. Control group: quercetin 0 μM, 24 h; Que-15: quercetin 15 μM, 24 h; Que-60: quercetin 60 μM, 24 h; Data are expressed as mean?±?standard deviation of three independent experiments. aP?<?0.01 compared with Normal group; bP?<?0.01 compared with Model group.
| [1] |
Hanumantharaju BK, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Manjunatha R. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol 2016; 48: 134-40.
DOI URL |
| [2] |
Foo KF. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol, 2019; 37: 1293-6.
DOI PMID |
| [3] |
Renggli M, Padrutt I, Michel E, Reichler I. Benign prostatic hyperplasia: treatment options in the dog. Schweiz Arch Tierheilkd 2010; 152: 279-84.
DOI URL |
| [4] |
Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5alpha-reductase inhibitors. JAMA Intern Med 2017; 177: 683-91.
DOI URL |
| [5] |
Strope SA, Yang L, Nepple KG, Andriole GL, Owens PL. Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia. J Urol 2012; 187: 1341-5.
DOI PMID |
| [6] |
Nishizawa O, Yoshida M, Takeda M, et al. Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. Int J Urol 2015; 22: 378-84.
DOI PMID |
| [7] | Chen W, Huang X, Peng A, et al. Kangquan recipe regulates the expression of BAMBI protein via the TGF-beta/Smad signaling pathway to inhibit benign prostatic hyperplasia in rats. Evid Based Complement Alternat Med 2019; 2019: 1-12. |
| [8] |
Yuan Y, Yang J, Zhu W, et al. Qianlongtong inhibits proliferation and induces apoptosis of hyperplastic prostate cells. Am J Mens Health 2018; 12: 1548-53.
DOI PMID |
| [9] | Wang Y, Yu W, Shi C, et al. Network pharmacology of Yougui pill combined with Buzhong Yiqi decoction for the treatment of sexual dysfunction. Evid Based Complement Alternat Med 2019; 2019: 1-10. |
| [10] | Chen Y, Shergis JL, Wu L, et al. A systematic review and meta-analysis of the herbal formula Buzhong Yiqi Tang for stable chronic obstructive pulmonary disease. Complementary Therapies in Medicine 2016; 2016: 94-108. |
| [11] |
Deng D, Chen Z, Jia L, et al. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial. Trials 2019; 20: 1-8.
DOI |
| [12] | Chen Z, Huang H, Chen QY. Effect of modified Buzhong Yiqi decoction combined with pelvic floor muscle exercise-biofeedback-electrical stimulation on early stage postpartum pelvic floor dysfunction. Zhong Guo Zhong Yao Za Zhi 2018 43: 2391-5. |
| [13] |
Jarrell JT, Gao L, Cohen DS, Huang X. Network medicine for Alzheimer's disease and Traditional Chinese Medicine. Molecules, 2018; 23: 1143.
DOI URL |
| [14] | Zhang RZ, Yu SJ, Bai H, Ning K. TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations. Sci Rep 2017; 7: 2821. |
| [15] | Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014; 6: 13. |
| [16] |
Sheng S, Wang J, Wang L, et al. Network pharmacology analyses of the antithrombotic pharmacological mechanism of Fufang Xueshuantong Capsule with experimental support using disseminated intravascular coagulation rats. J Ethnopharmacol, 2014; 154: 735-44.
DOI PMID |
| [17] |
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13: 2498-504.
DOI PMID |
| [18] |
Kim SS, Kim JH, Han IH, Ahn MH, Ryu JS. Inflammatory responses in a benign prostatic hyperplasia epithelial cell line (BPH-1) infected with Trichomonas vaginalis. Korean J Parasitol 2016; 54: 123-32.
DOI URL |
| [19] | Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 2015; 22: 1-6. |
| [20] | Ju WJ, Zhao ZK, Chen SL, et al. Buzhong Yiqi decoction Protects against loperamide-induced constipation by regulating the arachidonic acid pathway in rats. Front Pharmacol 2020; 2020: 423. |
| [21] |
Murakami Y. Clinical effect of hotyuekkito (Buzhong Yiqi Tang) on symptoms due to renal ptosis and stress incontinence. Hinyokika Kiyo, 1988; 34: 1841-3.
PMID |
| [22] |
Furuya Y, Akashi T, Fuse H. Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility. Arch Androl, 2004; 50: 11-4.
DOI PMID |
| [23] | Chen G, Huang C, Liu Y, et al. Network pharmacology approach to uncover the potential mechanism of Yinchensini Decoction. Evid Based Complement Alternat Med 2018; 2018: 1-14. |
| [24] |
Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. Nutrients 2016; 8:167.
DOI PMID |
| [25] |
Park KH, Yin J, Yoon KH, Hwang YJ, Lee MW. Antiproliferative effects of new dimeric ellagitannin from cornus alba in prostate cancer cells including apoptosis-related s-phase arrest. Molecules 2016; 21: 137.
DOI PMID |
| [26] |
Yin J, Heo JH, Hwang YJ, Le TT, Lee MW. Inhibitory activities of phenolic compounds isolated from adina rubella leaves against 5alpha-reductase associated with benign prostatic hypertrophy. Molecules 2016; 21:887.
DOI URL |
| [27] | Elberry AA, Mufti S, Al-Maghrabi J, et al. Immunomodulatory effect of red onion (Allium cepa Linn) scale extract on experimentally induced atypical prostatic hyperplasia in wistar rats. Mediators Inflamm 2014; 2014: 640746. |
| [28] |
Nunzio CD, Salonia A, Gacci M, et al. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia World J Urol 2010; 38: 2771-9.
DOI |
| [29] | Rodriguez-Berriguete G, Prieto A, Fraile B, et al. Relationship between IL-6/ERK and NF-kappa B: a study in normal and pathological human prostate gland. Eur Cytokine Netw 2010; 21: 241-50. |
| [30] |
Funahashi Y, Majima T, Matsukawa Y, et al. Intraprostatic Reflux of urine induces inflammation in a rat. Prostate 2017; 77: 164-72.
DOI PMID |
| [31] |
Dong-Hyun Y, Jinbong P, Hye-Lin K, et al. Berberine improves benign prostatic hyperplasia via suppression of 5 alpha reductase and extracellular signal-regulated kinase in vivo and in vitro. Front Pharmacol 2018; 9: 773.
DOI PMID |
| [32] |
Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013; 4: 342-59.
DOI PMID |
| [33] |
Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-9.
PMID |
| [34] | Gong F, Zhang Y, Lin J, et al. 1-(5-Bromo-2-hydroxy-4-methoxyphenyl) ethanone [SE1] inhibits MMP-9 expression by regulating NF-kappa B and MAPKs signaling pathways in HT1080 human fibrosarcoma cells. Evid Based Complement Alternat Med 2018; 2018: 1-9. |
| [35] |
Hamdy F, Fadlon E, Cottam D, et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1994; 69: 177-82.
DOI |
| [36] |
Zhang S, Wei G, Ren TT, et al. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs 2012; 23: 108-18.
DOI PMID |
| [37] | Babichenko II, Andriukhin MI, Pulbere S, et al. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. Int J Clin Exp Pathol 2014; 7: 9090-8. |
| [38] |
Eberhardt W, Huwiler A, Beck KF, Walpen S, Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 2000; 165: 5788-97.
PMID |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
